本帖最后由 老马 于 2012-1-13 21:20 编辑
! |+ G" b# R7 @; [7 s u4 X/ W
7 ]! V! q. Z7 K- Y爱必妥和阿瓦斯丁的比较
3 D1 j; `7 R. I% C) u
/ h9 e* t6 X8 Y, a1 c/ I* Y7 [
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/$ |; j- L8 h" Z4 s, ^
+ m P! K6 h* e* ]
8 Y' r( ]2 B2 [7 ihttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/6 [: t! u: r- k% K7 v6 ]
==================================================
3 K( Z1 V: |+ H& g5 n8 t: @Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)) z+ ~( Y, }3 Z' i( X' e: S, D
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
2 D# ]9 L% n6 `6 QResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
9 [# u) a. C5 V8 M$ L( K; L
|